Exenatide
Sources
registry, as of 2015-04-07Stale
https://clinicaltrials.gov/study/NCT00375492
Effect on Weight Loss of Exenatide Versus Placebo. Overall status COMPLETED. Phases PHASE3. Lead sponsor AstraZeneca. Enrollment 196. Conditions Type 2 Diabetes Mellitus. This trial is designed to compare the effects of twice-daily exenatide and twice-daily placebo on weight loss. This trial will evaluate overweight and obese subjects with type 2 diabetes who have inadequate glycemic control with metformin, sulfonylurea, or metformin plus a sulfon nausea Group A (Exenatide) 43 diarrhea Group A (Exenatide) 18 vomiting Group A (Exenatide) 21 nausea Group B (Placebo) 19 diarrhea Group B (Placebo) 21 vomiting Group B (Placebo) 9
ClinicalTrials.gov NCT00375492 protocol and results modules
registry, as of 2021-04-09Stale
https://clinicaltrials.gov/study/NCT03671733
Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese Patients. Overall status UNKNOWN. Phases PHASE3. Lead sponsor Xiangya Hospital of Central South University. Enrollment 150. Conditions Obesity. This studay evaluates the effect of the glucagon-like peptide-1 (GLP-1) receptor agonist,including Liraglutide,Exenatide and Exenatide Microspheres for Injection,in the treatment of subjects who are overweight or obese.
ClinicalTrials.gov NCT03671733 protocol and results modules
registry, as of 2019-06-04Stale
https://clinicaltrials.gov/study/NCT00856609
The Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese Subjects. Overall status COMPLETED. Phases PHASE3. Lead sponsor National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Enrollment 150. Conditions Weight Loss; Obesity. Exenatide is an incretin-like drug that has been approved for treatment of type 2 diabetes; it improves glycemia by increasing insulin and decreasing glucagon secretion by pancreatic islet cells and delaying gastric emptying. This randomized, placebo-controlled study is to evalua deaths Exenatide 0 nausea Exenatide 24 diarrhea Exenatide 16 vomiting Exenatide 11 deaths Placebo 0 nausea Placebo 19 diarrhea Placebo 16 vomiting Placebo 8
ClinicalTrials.gov NCT00856609 protocol and results modules
registry, as of 2021-01-29Stale
https://clinicaltrials.gov/study/NCT02635386
EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS). Overall status COMPLETED. Phases PHASE3. Lead sponsor Woman's. Enrollment 119. Conditions Polycystic Ovary Syndrome; Obesity. This is a randomized, single-blind, parallel 5 treatment group 24-week trial designed to directly compare the therapeutic effects of exenatide once weekly (EQW), dapagliflozin (DAPA), EQW plus DAPA, combined DAPA/metformin extended release (XR) and the weight loss medication, phe Change in Percent Body Weight Exenatide Once Weekly (EQW ) 3.8 percentage change in body weight Change from baseline (time 0) to study end (24 weeks) Change in Percent Body Weight Dapagliflozin (DAPA) 1.5 percentage change in body weight Change from baseline (time 0) to study end (24 weeks) Change in Percent Body Weight EQW Plus DAPA 6.9 percentage change in body weight Change from baseli
ClinicalTrials.gov NCT02635386 protocol and results modules
registry, as of 2026-01-05Stale
https://clinicaltrials.gov/study/NCT04520490
Brain Activation and Satiety in Children 2. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Seattle Children's Hospital. Enrollment 63. Conditions Childhood Obesity. Childhood obesity and related long-term effects are serious public health problems, but not all children with obesity do well in treatment. This study will test a new combination of family-based behavioral treatment (FBT) with a drug intervention using a glucagon-like peptide-1 r
ClinicalTrials.gov NCT04520490 protocol and results modules
registry, as of 2015-06-24Stale
https://clinicaltrials.gov/study/NCT01794429
Treatment of Antipsychotic-associated Obesity With a GLP-1 Analogue. Overall status COMPLETED. Phases PHASE3. Lead sponsor Bjorn H. Ebdrup. Enrollment 45. Conditions Obesity; Metabolic Syndrome X; Drug-induced Obesity; Schizophrenia. To examine if 3 months of treatment with a GLP-1 (glucagon-like-peptide-1) analogue can induce weight loss in obese, non-diabetic patients with a diagnosis within the schizophrenic spectrum. The investigators will also examine possible associations between GLP-1 treatment and pe
ClinicalTrials.gov NCT01794429 protocol and results modules
registry, as of 2026-05-22Stale
https://clinicaltrials.gov/study/NCT02860923
Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy. Overall status COMPLETED. Phases PHASE3. Lead sponsor University Hospital, Bordeaux. Enrollment 42. Conditions Craniopharyngiomas; Hypothalamic Obesity. This hypothalamic obesity is associated with serious metabolic and psychosocial consequences. The purpose of the study is to compare the change of body weight after 6 months treatment with a lifestyle intervention + exenatide compare to the one after the same lifestyle intervent
ClinicalTrials.gov NCT02860923 protocol and results modules
registry, as of 2022-05-05Stale
https://clinicaltrials.gov/study/NCT02664441
Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity. Overall status COMPLETED. Phases PHASE3. Lead sponsor Seattle Children's Hospital. Enrollment 42. Conditions Hypothalamic Obesity. The proposed multicenter study will test the effect of glucagon-like peptide (GLP)-1 agonist exenatide once weekly extended-release (ExQW, Bydureon®) on clinical outcomes and metabolic parameters in a double-blind, placebo-controlled 36 week randomized trial with an 18 week open Percent Change of Body Mass Index (BMI) as Calculated by the Formula: Body Weight in kg Divided by Height in Meters². Exenatide Once Weekly Extended-release 1.7 percent change from baseline From baseline to 36 weeks Percent Change of Body Mass Index (BMI) as Calculated by the Formula: Body Weight in kg Divided by Height in Meters². Matching Placebo 3.5 percent change from ba
ClinicalTrials.gov NCT02664441 protocol and results modules
registry, as of 2009-03-31Stale
https://clinicaltrials.gov/study/NCT00872378
The Effects of Exenatide After Gastric Restriction. Overall status UNKNOWN. Phases PHASE2,PHASE3. Lead sponsor Advanced Specialty Care. Enrollment 28. Conditions Morbid Obesity. The purpose of this study is to describe change in body weight in non-diabetic morbidly obese patients after laparoscopic adjustable gastric banding (LAGB) with twice daily exenatide or placebo injections.
ClinicalTrials.gov NCT00872378 protocol and results modules
registry, as of 2020-03-31Stale
https://clinicaltrials.gov/study/NCT03419624
The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients. Overall status TERMINATED. Phases PHASE3. Lead sponsor Universitätsklinikum Hamburg-Eppendorf. Enrollment 13. Conditions Obesity; Diabetes Mellitus, Type 2. This is a 28-week, multi-center, randomized, double-blind, placebo-controlled trial to study a potential synergistic effect of Dapagliflozin plus Exenatide once-weekly in combination with high-dose intensive insulin therapy compared to Placebo in obese insulin-resistant patients
ClinicalTrials.gov NCT03419624 protocol and results modules
registry, as of 2015-04-07Stale
https://clinicaltrials.gov/study/NCT00500370
A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese Patients. Overall status COMPLETED. Phases PHASE2. Lead sponsor AstraZeneca. Enrollment 163. Conditions Obesity. This is a multicenter study designed to compare the effect of exenatide plus a lifestyle modification plan versus placebo plus a lifestyle modification plan on weight loss in non-diabetic, obese subjects. Percentage of Patients Experiencing >=5% Weight Loss Group A (Exenatide) 31.5 Percentage of Patients Experiencing >=5% Weight Loss Group B (Placebo) 16.5 nausea Group A (Exenatide) 18 diarrhea Group A (Exenatide) 10 vomiting Group A (Exenatide) 6 nausea Group B (Placebo) 3 diarrhea Group B (Placebo) 2 vomiting Group B (Placebo) 1
ClinicalTrials.gov NCT00500370 protocol and results modules
registry, as of 2021-01-28Stale
https://clinicaltrials.gov/study/NCT02975297
Exenatide Once Weekly for Smoking Cessation. Overall status COMPLETED. Phases PHASE1,PHASE2. Lead sponsor The University of Texas Health Science Center, Houston. Enrollment 84. Conditions Smoking Cessation. The purpose of this study is to identify a potential new treatment for smoking cessation. deaths Exenatide Plus NRT Plus Counseling 0 deaths Placebo Plus NRT Plus Counseling 0
ClinicalTrials.gov NCT02975297 protocol and results modules
registry, as of 2007-07-11Stale
https://clinicaltrials.gov/study/NCT00344851
Exenatide and Metformin Therapy in Overweight Women With PCOS. Overall status COMPLETED. Phases PHASE2. Lead sponsor Metabolic Center of Louisiana Research Foundation. Enrollment 60. Conditions Polycystic Ovary Syndrome. Current research has shown that the use of diabetes management practices aimed at reducing insulin resistance and hyperinsulinemia (such as weight reduction and the administration of oral antidiabetic drugs) in women with PCOS can not only improve glucose and lipid metabolism but
ClinicalTrials.gov NCT00344851 protocol and results modules
registry, as of 2016-11-17Stale
https://clinicaltrials.gov/study/NCT02313220
Exploratory Study to Investigate the Effect of Dapagliflozin and Exenatide Combined on Body Weight. Overall status COMPLETED. Phases PHASE2. Lead sponsor Uppsala University. Enrollment 50. Conditions Obesity. Obesity is a medical condition which increases the risk of other diseases, such as type 2 diabetes and cardiovascular disease. Obesity-related risk factors for the development of other metabolic diseases include unstable glucose levels and high blood pressure. Dapagliflozin and e
ClinicalTrials.gov NCT02313220 protocol and results modules
registry, as of 2022-05-18Stale
https://clinicaltrials.gov/study/NCT02794402
Double-blinded, 6 Months Study With Bydureon® or Placebo in Adolescents With Obesity to Explore Changes in BMI. Overall status COMPLETED. Phases PHASE2. Lead sponsor Uppsala University. Enrollment 44. Conditions Obesity. Combat-JUDO (Combating Juvenile Diabetes and Obesity through normalization of beta-cell function) is part of a collaborative project funded by the Seventh Framework Programme of the European Commission aiming to develop innovative therapeutic strategies by increasing pharmacology
ClinicalTrials.gov NCT02794402 protocol and results modules